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Abstract
There is increasing evidence that alterations in chromatin remodeling play a significant role in
human disease. The SWI/SNF chromatin remodeling complex family mobilizes nucleosomes and
functions as a master regulator of gene expression and chromatin dynamics whose functional
specificity is driven by combinatorial assembly of a central ATPase and association with 10-12
unique subunits. While the biochemical consequence of SWI/SNF in model systems has been
extensively reviewed, the present article focuses on the evidence linking SWI/SNF perturbations
to cancer initiation and tumor progression in human disease.
The SWI/SNF family of chromatin remodeling complexes are master regulators of
transcription factor action and resultant gene expression programs. SWI/SNF complexes are
large, ~2 MDa multi-subunit conglomerates that serve to either enhance or suppress gene
transcription through mobilization of nucleosomes(1, 2). Intriguingly, mounting evidence
supports the paradigm that specificity of SWI/SNF action evolves through combinatorial
assembly of 10-12 subunits, and that “imbalances” in subunit composition are frequently
observed in human cancers. While the functions of SWI/SNF in transcriptional control and
development have been extensively reviewed(1-6), the present study will focus exclusively
on the role of SWI/SNF and its subunit dysregulation in tumorigenesis, disease progression,
and therapeutic resistance.
Diversity in SWI/SNF composition: a brief overview
SWI/SNF subunits can be grossly sub-classified into three categories: i) enzymatic
(ATPase), ii) core subunits, and iii) accessory subunits (7). While the precise mechanisms
by which SWI/SNF modifies chromatin structure remain incompletely understood, this
process is thought to involve ATPase-dependent disruption of histone-DNA association and
resultant nucleosome “sliding”(2, 7). Accordingly, each SWI/SNF complex incorporates one
of two possible ATPases, BRM (Brahma) or BRG1 (Brahma-Related Gene 1), that share
75% amino acid identity. Based on these observations, one might expect that the ATPases
serve overlapping cellular functions and follow similar disruption patterns in human disease.
By contrast, laboratory and clinical evidence, discussed within this article, suggest that the
two ATPases frequently show differentially altered expression patterns and in vivo
functions.
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Accompanying each ATPase are 10-12 proteins known as BAFs (BRG1 or BRM-associated
factors) consisting of “core” and “accessory” subunits (Figure 1). The “core” subunits,
BAF155, BAF170, and SNF5 (also referred to as SMARCB1, BAF47 or INI1), were
functionally classified based on their ability to restore efficient nucleosome remodeling in
vitro(8, 9). BAF155 maintains a scaffolding-like function, and can influence both stability
and assembly of other SWI/SNF subunits(10). The function of BAF170, which shares
homology with BAF155, is less well understood, but may also control the levels of other
SWI/SNF subunits. Given these activities, the roles of BAF155 and BAF170 as core
subunits can be readily conceptualized. By contrast, the function of SNF5 is divergent, as
this subunit contains an intrinsic, non-specific, DNA-binding domain. Much emphasis has
been placed on delineation of SNF5 action, as this subunit is a bona fide tumor suppressor
gene in malignant rhabdoid tumor development, and regulates expression of critical
proliferative control genes(11, 12). Thus, the core SWI/SNF subunits encompass widely
distinct biochemical and functional activities.
The accessory subunits are hypothesized to dictate specificity of SWI/SNF complex function
(1, 4). These subunits include BAF60a, b, and c, encoded by 3 distinct genes and present in
only one copy per complex. The BAF45a-d and BAF53a and b accessory subunit classes are
similarly encoded by multiple genes, but the relevance of each for overall SWI/SNF
function and combinatorial assembly remains incompletely defined. Established
demonstration of specificity arises from the BAF250a, b and BAF180 subunits, which
define the BAF and PBAF versions of SWI/SNF complexes, respectively. BAF180
incorporation into SWI/SNF is mutually exclusive with the presence of BAF250a or
BAF250b. Additional specificity factors with a suggested role in human disease include
BAF57, BAF200, BAF53a, and beta-actin. Overall, the relative abundance and
combinatorial assembly of these subunits has been elegantly compared to a chromatin-
remodeling “language”, wherein the subunit ‘letters’ can be assembled into at least 288
distinct words, each with possible alternative cellular outcomes (1). In keeping with this
concept, specific SWI/SNF combinations have been recently implicated with pluripotency
and therefore deemed esBAFs(13). By contrast, it is apparent in human cancer that disease-
associated ‘misspellings’ can contribute to disease initiation, progression, and metastasis.
Cancer initiation
Incontrovertible evidence supports the contention that SWI/SNF alterations contribute to
tumorigenesis. Intriguingly, these alterations frequently entail tissue/tumor-specific loss of
individual subunits, resulting in elimination of specific SWI/SNF complexes and possible
creation of new combinatorial assemblies. While the biochemical consequence of SWI/SNF
subunit loss is currently under active investigation, SWI/SNF misregulation appears to play
a subunit and tissue specific role in cancer initiation (Figure 2).
ATPases: specialized tumor suppressors?
Extensive analyses support tissue and tumor-specific roles of SWI/SNF ATPase subunit loss
in tumor development. Several reports have shown mutations and/or loss of BRG1 in human
cancer cell lines and primary tumors (14-20). Supporting a role in cancer initiation, loss of
heterozygosity (LOH) of the region surrounding BRG (21) occurs with significant frequency
in human adenocarcinomas (22-27). Interest in this region is heightened by the presence of
the Peutz-Jeghers multiple adenocarcinoma syndrome gene, STK11/LKB1, which maps 8.5
Mb distally from BRG1(26-30) (Figure 3). Importantly, chromosome transfer studies
mapped tumor suppressor function to this region (31, 32), and at least one report localized
the tumor suppressor gene to a region containing BRG1 but lacking STK11(32), thereby
suggesting that selected cancers may arise from BRG1 mutations rather than aberrant STK11
function. Alternatively, BRG1 loss could occur as a secondary event in a subset of tumors
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that have deletions of the STK11 gene. Complementing these findings, studies in genetically
engineered mice models (GEMM) showed that while germline loss of BRG1 leads to early
embryonic lethality, Brg1 heterozygous animals develop mammary adenocarcinomas due to
haploinsufficiency (33, 34). Recent reports also demonstrated an increased frequency of
lung adenocarcinomas in Brg1+/- mice exposed to the carcinogen urethane (35), and
inactivating mutations of BRG1 have been identified in human lung cancer cell lines(36).
Whether these results indicate that the reduced levels of BRG1 initiates tumor development
in a rare population of cells or promotes tumor progression in a rare population of initiated
cells remains unresolved, but provide strong indication that BRG1 possesses tumor
suppressor functions.
Despite the molecular similarities in function between BRG1 and BRM, the pattern and
influence of BRM loss on tumorigenesis is largely distinct from that of BRG1. Disparity in
requirement for BRG1 versus BRM was first noted as a result of GEMM, wherein it was
revealed that Brm-/- animals are viable, fertile, and slightly larger than wild-type littermates
(37). Closer examination led to discovery of links between BRM loss and human disease. In
the lung, exposure of Brm-/- animals to ethyl carbamate results in increased development of
lung adenomas, thus implicating a role for BRM loss in lung cancer development(38).
Further supporting this premise, BRM is downregulated in up to 30% of lung cancer cell
lines analyzed, and is reduced at high frequency in both non-small cell lung
adenocarcinomas and squamous cell carcinomas(18). These data provide compelling
evidence for BRM loss as a contributory factor in lung tumorigenesis. Similar observations
were deduced in examination of prostatic tissue, wherein loss of BRM has been identified in
multiple studies as associated with prostatic adenocarcinoma (39, 40), and additionally
shown to correlate with a higher proliferative index (40). These observations were further
supported by examination of Brm-/- mice, wherein lobe-specific hyperplasia of the prostate
was observed. In contrast to most observations in the lung, reduced SWI/SNF ATPase
expression in the prostate was limited to the BRM subunit, and BRG1 expression was
reported to be sustained at or above levels in non-neoplastic tissue. Striking parallels are
observed in gastric cancer, wherein BRM loss correlates with histologic subtype(41).
Examination of 27 cell lines and 89 primary tumors revealed that BRM loss is a significant
marker of tumorigenesis, and promotes loss of villin, a well-established differentiation
marker. Additional observations of BRM loss have been reported in esophageal, ovarian,
bladder, colon, and breast cancer cell lines, but the impact of these events on tumor
phenotypes has yet to be explored(42, 43). Nonetheless, these observations implicate BRM
loss as a contributing factor and potential marker of tumorigenesis in lung, prostate, and
gastric cancers. Together, these findings indicate that BRG1 and BRM ATPases serve
specialized tumor suppressor like functions in human tissue.
Core subunits
Consistent with the consequence of ATPase subunit disruption, alteration of the selected
core SWI/SNF subunits is associated with tumor initiation. The smallest core subunit, SNF5,
behaves as a bona fide tumor suppressor gene. Mutations or deletions of the human SNF5
gene (SMARCB1) were initially reported in >80% of renal and extrarenal malignant
rhabdoid tumors (MRTs) (44). Subsequent analyses found loss of function mutations in
nearly 100% of both renal and extrarenal MRTs and cell lines (45-47). Thus, multiple
reports have established that mutations in this gene occur in the vast majority of sporadic
human MRTs while germ line mutations are associated with non-penetrant familial MRT
syndrome (44-55). Mutations in SNF5 appear confined to a narrow range of tumors
including MRTs, epithelioid sarcomas, renal medullary carcinomas, and recently, familial
schwannomatosis (54, 56-58). Other reports have also implicated SNF5 loss in the
development of choroid plexus carcinomas (59, 60). As would be expected based on these
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clinical observations, complete loss of SNF5/INI1 expression leads to early embryonic
lethality in GEMM (61-63). However, Snf5/Ini1+/- mice develop tumors with features of
human MRTs in up to 60% of the animals beginning at 8 months (61-64). A conditional
mutant that causes only partial penetrance of SNF5 leads to tumor development in 100% of
the mice by 13 weeks (64). These results clearly establish that the SNF5 gene acts as a
classical tumor suppressor gene and initiates tumor development in a similar fashion to the
RB1, BRCA1 and APC genes.
As noted above, the remaining core subunits of BAF155 and BAF170 have been shown to
regulate assembly and overall levels of other SWI/SNF subunits (10, 65). Therefore, one
might predict that loss of either subunit might initiate tumor development or fuel tumor
progression. As yet, there is little evidence linking BAF170 to human cancers. BAF155,
however, resides in a region of chromosome 3, band p21.31, that includes other suspected
tumor suppressor genes, such as SEM3B and FUS1 (66, 67). Surprisingly, BAF155 is
markedly induced in prostate cancer, and correlates with both tumor recurrence and
dedifferentiation (68). Moreover, recent reports have found increased expression of BAF155
mRNA in cervical intraepithelial neoplasia (CIN), prostate cancer and colorectal cancer
(68-71). However, the increased BAF155 mRNA levels were found in early stage dysplastic
cervical lesions and were associated with a significantly better overall survival rate (70).
These collective findings could indicate that aberrations in overall BAF155 levels may
contribute to tumor initiation, dependent on context. Given the ability of BAF155 to control
levels of other SWI/SNF subunits, it is intriguing to speculate that deregulated BAF155
expression may result in markedly altered availability of SWI/SNF subunits and a shift in
the possible combinatorial assemblies. Based on these collective findings, it has become
clear that while the loss of one core subunit, SNF5, can promotes tumorigenesis in a subset
of human tissues, changes in expression in the BAF155 subunit may inhibit or promote
tumor initiation or progression in cell or tissue specific manner.
Accessory subunits
Consistent with the posit that there is selective pressure in human cancer for alterations in
SWI/SNF complex function, cancer-associated perturbations in expression have also been
reported for the BAF250a, BAF180, BAF60, and BAF57. In a functional screen of 4
primary breast tumors and 3 primary prostate tumors, Huang et al. identified a deletion in
the BAF250a gene (72). At what stage this event contributes to tumorigenesis remains
untested, although functional studies have implicated BAF250 complexes as master
regulators of cellular proliferation (73). Preliminary evidence also points toward a role for
BAF180 and BAF60 subunits in proliferative control and tumor prevention. Truncating
mutations in the BAF180/PBRM1 gene were identified in 2 human breast tumor cell lines
and in 2/52 primary breast tumors, and functional analyses revealed that these mutations
induce loss of cell cycle regulatory activity (74). Concordant with these observations,
multidimensional LC-MS/MS identified reduced BAF180 protein expression in HNSCC
compared to normal head and neck controls (71). As for the BAF60 subclass, BAF60a
interacts directly with the p53 tumor suppressor, and in model systems supports both p53-
mediated apoptosis and cell cycle arrest signals(75). Reduced BAF60c gene expression was
associated with early stage neuroblastoma(76), therefore providing preliminary evidence
that BAF60 subunits may be lost or downregulated in selected tumor types. Lastly,
alterations in BAF45d have been primarily implicated in breast cancer, as SNPs in the 5’
region of the gene are associated with increased risk, lymph node metastases, and tumor
burden(77). Collectively, these observations point toward a role for BAF250a, BAF60a/c,
BAF180, and BAF45d in tissue-specific tumor prevention.
In contrast, the role of the BAF53a and BAF57 accessory subunits appears variable.
BAF53a interacts with p53 and assists in p21CIP1 induction(78), implicating this subunit in
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the cytostatic response to DNA damage. However, BAF53a is requisite for the oncogenic
funtion of c-Myc, and is itself associated with mitotic chromosomes(79). The impact of
these functions on tumor phenotypes awaits further investigation, as does analyses of
BAF53a expression in human disease. Interestingly, the BAF57 subunit has been shown to
harbor enhanced expression or activity in human tumors, especially with regard to the
hormone-dependent cancers. In breast cancer cell lines, mutations in BAF57 were reported
which increased the response of the estrogen receptor to a critical transcriptional cofactor,
SRC1(80, 81). The frequency of these mutations and impact on breast cancer development
or phenotypes awaits further analyses. In prostate cancer, BAF57 binds and facilitates
activity of the androgen receptor (AR), a nuclear receptor and essential factor for prostate
cancer development(82). Notably, studies reported elevated BAF57 levels in a subset of
primary and lymph node prostate cancers, lending preliminary credence to the supposition
that BAF57 function may be enhanced in steroid-hormone receptor dependent tumor
types(83). Similar to observations with BAF180, these results suggest that elevation or gain-
of-function alterations in BAF57 may significantly influence SWI/SNF function and confer
pro-tumorigenic properties to the resulting complexes. Together, these intriguing findings
suggest that unlike the central ATPases, loss or gain of specific accessory subunits may
assist in cancer initiation, and provide the impetus to discern the consequence of altered
subunit expression on SWI/SNF assembly and tumor endpoints.
Progression and therapeutic response: unique roles for the ATPases
While the majority of published SWI/SNF studies have probed the consequence of subunit
dysfunction for tumorigenesis, emerging evidence is indicative of specialized SWI/SNF
subunit roles in tumor progression and therapeutic response. Global diminution of SWI/SNF
activity (via loss of BRG1 and BRM) in non-small cell lung carcinoma correlates with poor
overall survival, providing some of the strongest indication that overall SWI/SNF activity
protects against tumor progression (15, 18). For BRG1, several lines of evidence support the
notion that its loss can contribute to neoplastic development during later stages rather than in
early steps. For example, Brg1+/- mice develop mammary adenocarcinomas at a low
penetrance (~12%) at approximately 12 months, despite showing no LOH in the tumors (33,
34). These results suggest that reduced BRG1 may allow a rare population of initiated cells
to progress to neoplasia; otherwise, one would expect a more fulminant tumor phenotype in
the Brg1+/- mice considering the haploinsufficient phenotype of the mammary tumors.
While many human tumor cell lines lack detectable BRG1 and BRM expression, BRG1-
deficient mouse fibroblasts and embryonal carcinoma cells paradoxically fail to proliferate
or grow poorly in culture (33, 35, 84), and show dissolution of chromatin structure (Buorgo
et al., in press). Apoptosis was observed in lung epithelia in vivo after deletion of both Brg1
alleles (35). Taking these observations into account, it has been hypothesized that
acquisition of cooperative genetic events during cellular transformation is needed to allow
proliferation in the absence of BRG1 and BRM. Further supporting the notion that BRG1
loss can contribute to tumor progression, high frequency of LOH (75%) in NSCLC was
shown to occur in late stage and metastatic samples but not early stage disease (25). Most
dramatically, loss of BRG1 expression in acute lymphoblastic leukemia (ALL) strongly
correlated with therapeutic resistance to prednisolone, and subsequent in vitro modeling
showed that BRG1 knockdown was sufficient to achieve therapy resistance (85). Some
parallels with SNF5 are noted, as downregulation of this subunit has also been linked to
steroid resistance in ALL (85-87). While the resultant tumor phenotypes are distinct in
different tissues, these data strongly support a role for BRG1 loss in tumor progression.
Unique profiles of loss and tumor progression were also observed with the BRM ATPase.
Exemplifying the distinction between subunits, BRM but not BRG1 loss is a hallmark of the
“poor” (poorly differentiated) form of gastric cancer, which is associated with unfavorable
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prognosis (41). Mouse models also hint toward a link between BRM loss and therapeutic
response in prostate cancer, as Brm deletion resulted in modest androgen-independent
cellular proliferation of selected prostatic epithelia in vivo (40). Since androgen deprivation
is the first line of therapeutic intervention for patients with disseminated disease, and the
ability of tumors to circumvent androgen ablation (referred to as the transition to castration-
resistant prostate cancer) represents an incurable phase, investigation of BRM loss on this
event warrants further investigation. BRM status and response to hormonal-based therapies
may also be of interest in breast cancer, since BRM is critical for the in vitro response to
tamoxifen (88). BRM may also modify the response to genotoxic stress, as BRM loss alters
DNA damage checkpoints in vitro (37), and loss of BRM occurs as an early response to
ionizing radiation in esophageal squamous cell carcinomas. Most significantly, BRM loss
was identified as an indicator of poor prognosis in non-small cell lung cancer. Patients with
lung adenocarcinomas or squamous cell carcinomas incurred a 5-year survival rate of 72% if
positive for BRM and BRG1, but only 32.3% if deficient in BRM or BRG1. Intriguingly,
altered subcellular (membrane) localization of BRM was associated with a 16.7% survival
rate (15). These findings are striking, as of 12 chromatin remodeling proteins examined,
only BRM showed prognostic significance. Based on these findings, it is clear that the
mechanisms by which BRM alters therapeutic response and alters the course of disease
should be determined.
Despite the evidence linking ATPase alterations to tumor development and progression, few
studies have addressed the impact of SWI/SNF function on invasion and metastasis in the
clinic, and the GEMM provided little evidence linking loss of SWI/SNF to a metastatic
phenotype. Therefore, only in vitro studies have provided clues regarding a potential role for
alterations in complex subunit expression in metastasis. In vitro restoration of BRM in
BRM-deficient lung cancer cells resulted in reduced soft agar and invasion capabilities(38),
thus giving some indication that BRM may influence lethal tumor phenotypes. Additionally,
BRG1 and/or BRM can regulate the expression of proteins associated with metastatic spread
in a variety of human cancers, including CD44, CDH1 and actin filament organization
(89-91). While these findings are provocative, further studies are needed using primary
human tumor material and GEMM to definitively address the role of the SWI/SNF ATPases
in the metastatic phenotype.
Within the core and accessory subunit categories, scant evidence exists to determine whether
these subunits contribute to tumor progression. A recent report showed that loss of SNF5
protein expression occurs in renal medullary carcinoma, a rare malignancy associated with
young adults, or in children with sickle cell trait or disease (92). In the case of MRT, it could
be argued that SNF5 loss may play a role in tumor progression because no other report of
additional genetic defects has appeared in the literature (93). However, most studies have
examined only primary tumors and MRT cell lines and may have missed secondary genetic
events. Progressive disease, metastases, and recurrences should be examined and compared
with primary disease so that later events can be examined. For the accessory proteins, the
individual subunits show widely varied influences on progression and treatment.
Interestingly, BAF57 was recently identified in a high-throughput shRNA library screen as
one of 5 genes (along with SNF5) required for the response of CML to imatinib(94). The
same study identified BAF250a as required for the response to Fas ligand, thus further
implicating the SWI/SNF subunits as putative effectors of chemotherapy. BAF45a, although
known for a role in neural progenitor cells(7), was recently identified in a gene signature
indicating favorable prognosis in colorectal cancer.
Based on these findings, it can be concluded that the SWI/SNF ATPases appear to have
significant, disparate roles in protecting against tumor progression. The requirement of
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individual cooperating subunits for these functions will be of the utmost importance to
discern.
Conclusions and future directions
Based on the published observations described herein, it is evident that perturbations in
SWI/SNF expression and function play substantive, subunit and tissue specific roles in
human cancers. As such, several critical questions should be addressed. First, what is the
basis of BRG1 and BRM-associated anti-tumorigenic functions? Loss of a central ATPase
BRG1 or BRM, appears to significantly contribute to both tumor development and tumor
progression, dependent on context, and emerging evidence supports a role for ATPase loss
in promoting therapeutic resistance. While these findings identify BRG1 and BRM as
candidate tumor suppressors, it remains unclear how these properties are exerted at the
cellular level. Second, what is the impact of a single ATPase loss on the formation of
remaining SWI/SNF complexes? This is a critical question, as current clinical evidence
suggests that loss of only one ATPase is typically observed, thus leading to speculation
about whether it is loss of that subunit or alterations in the remaining complexes that is
tumor driving. For example, in tumors that select for BRM loss, remaining SWI/SNF
complexes must shift to rely on BRG1-driven SWI/SNF chromatin remodeling. It should be
determined how these alterations might alter the number and composition of resultant
BRG1-associated complexes, and whether it is loss of BRM per se or “re-wiring” or
increased levels of BRG1-associated complexes that promotes tumor phenotypes. Third,
how do perturbations of accessory or core subunits alter tumorigenesis or progression?
Although SNF5 has been confirmed as a specific tumor suppressor, the underlying
mechanisms of action remain incompletely defined. Moreover, it is unclear how elimination
of a core subunit may alter the function of remaining SWI/SNF complexes. Similar
questions arise for BAF250a, BAF180, BAF60, BAF155, and BAF57, for which gains and
losses have been shown to promote tumorigenesis in disparate tissues. Fourth, what
mechanisms drive tumor-specific subunit alterations? Because substantial evidence supports
the notion that different tumor types select for differential SWI/SNF subunit perturbations,
we must determine what pro-tumorigenic properties each subunit alteration confers, and
how these support tumor growth in a particular tissue environment. Fifth, what is the basis
of imbalances in SWI/SNF subunit expression? While there is some evidence for genetic
mutation and LOH, in most cases the basis of subunit loss or gain remains undefined.
Investigation of such may provide important clues as to cooperating factors and mechanisms
of alteration that promote human disease. Sixth, are there emerging global paradigms that
explain these seemingly disparate observations about the role of the SWI/SNF complex in
human tumorigenesis? Despite the apparent context- and tumor-specific differences found
by different investigators, we find some potential areas of overlap. One fruitful area of
investigation may lie in the well-established link between the SWI/SNF complex and
nuclear receptor activity (95). Several studies have shown the effects of SWI/SNF complex
alterations on estrogen and androgen signaling in human tumor cell lines (80, 82, 83, 96).
Other reports showed a role for nicotinic acetylcholine receptors in NSCLC development,
where BRG1 and BRM loss occurs frequently (97). A link has also been established
between the loss of SWI/SNF complex function and epigenetic alterations in human tumor
cell lines (90). This raises the interesting possibility that alterations in SWI/SNF complex
activity could promote “epigenetic instability” in different human cancers, dependent upon
the subunit loss. Lastly, what are the clinical ramifications of overall SWI/SNF
“imbalances” taking all subunits into account? Early evidence has implicated imbalances in
individual subunits with critical outcomes such as tumor development, proliferation,
metastasis, therapy resistance, and patient survival. It should be determined if profiling of
multiple SWI/SNF subunits provides greater prognostic or predictive value, and how these
observations might be most effectively harnessed for clinical utility. In sum, hijacking of
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SWI/SNF function clearly provides a powerful tool through which tumor cells can re-wire
gene transcription and promote tumorigenesis; further investigation of this process is
expected to reveal new nodes of possible therapeutic intervention.
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Figure 1. SWI/SNF subunits
Distinct SWI/SNF complexes are formed by combinatorial assembly of a central ATPase
(pink), the core subunits (green), and selected accessory subunits (purple). Aliases and gene
identifications for each known subunit are provided.
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Figure 2. SWI/SNF alterations in human disease
Aberrant SWI/SNF expression has been reported in many tumor types. Alterations are
summarized as shown. Arrows indicate enhanced or decreased expression. M indicates
mutation.
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Figure 3. Ideogram of SWI/SNF subunit alterations in selected tumor types
Chromosomal locations of individual subunits are shown, and colors correspond to
subclassifications shown in Figures 1 and 2. Areas of chromosomal gain are shown in blue
and chromosomal loss in red. Areas of chromosomal gain and loss are not a complete survey
of all human tumors, but represent data from tumors associated with SWI/SNF alterations
including prostate, breast and NSCLC. Adjacent genes of cancer relevance are as indicated.
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